Lonza Group AG (SWX:LONN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 35.49B -7.6% |
| Revenue (ttm) | 6.53B -1.6% |
| Net Income | -275.00M |
| EPS | -3.93 |
| Shares Out | 69.84M |
| PE Ratio | 39.15 |
| Forward PE | 28.21 |
| Dividend | 5.00 (0.98%) |
| Ex-Dividend Date | May 12, 2026 |
| Volume | 21,564 |
| Average Volume | 173,166 |
| Open | 503.00 |
| Previous Close | 508.20 |
| Day's Range | 501.60 - 505.80 |
| 52-Week Range | 454.60 - 605.20 |
| Beta | 0.89 |
| RSI | 47.98 |
| Earnings Date | Apr 1, 2026 |
About Lonza Group AG
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanc... [Read more]
Financial Performance
Financial StatementsNews
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Performance Research
Simulations Plus (SLP) Partners with FDA and Lonza for Drug Performance Research
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG
DALLAS & NEW YORK & LONDON & TOKYO--(BUSINESS WIRE)--Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the ...
LZAGY, DSDVY: Investment Opportunities Outside of the U.S.
U.S. equity markets have benefitted from a perceived quality advantage over Europe, though it's uncertain when outperformance will end, notes Bryan Lee. He discusses finding investment opportunities o...
Lonza chairman to step down, drugmaker confirms targets, shares soar
Lonza said on Friday Chairman Albert Baehny will step down in May after six years in the job, in a second senior management reshuffle in recent months as the Swiss contract drug manufacturer grapples ...
Lonza CEO departure prompts concern over earnings prospects
Contract drug manufacturer Lonza said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor confidence about th...
10 Solid Stocks WIth Terrible Tickers
Stocks with long symbols are difficult to remember and easy to overlook. That would be a mistake.
Lonza's first-half core EBITDA gains 16.5%
Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from drugmakers.
Should You Have Lonza Stock on Your Watchlist?
If it's stability you're looking for, probably so.
Lonza appoints Novartis executive as new Chief Financial Officer
Lonza has appointed former Novartis executive Philippe Deecke as its new Chief Financial Officer, the Swiss chemicals company said on Thursday.
12 European Stocks That Analysts Love and Investors Are Ignoring
The stocks could turn out to be winners in coming months if analysts' upbeat calls turn out to be correct.
aTyr Pharma Recruits Lonza As Manufacturing Partner For Cancer Therapy ATYR2810
aTyr Pharma Inc (NASDAQ: LIFE) and Lonza Group Ltd (OTCMKTS: LZAGF) have agreed to manufacture ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical devel...
Lonza shortlists Lanxess, private equity in unit sale, sources say
Swiss contract drug maker Lonza has shortlisted German chemicals group Lanxess and private equity groups in the sale of its Lonza Specialty Ingredients (LSI) unit worth more than 3 billion Swiss franc...
Lonza Swipes a Top Roche Executive to Be Its Next CEO
Pierre-Alain Ruffieux will lead the contract development and manufacturing organization.